The intrastratial injection of an adenosine A(2) receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's disease.
The influence of 3,7-dimethyl-1-propargylxanthine (DMPX) an adenosine A(2) receptor antagonist, was studied in the quinolinic acid (QA) model of Huntington's disease. Male Wistar rats received bilateral intrastriatal injections of QA (300 nmol) alone or plus DMPX (0.02, 0.2 and 2 microg). At the dose of 0.2 microg, DMPX completely prevented QA-induced EEG abnormalities at the level of frontal cortex. The results support the hypothesis of a neuroprotective role of adenosine A(2) receptor antagonists.
Reggio
R
R
Department of Pharmacology, Istituto Superiore di Sanità, Viale Regina Elena, 299 00161, Rome, Italy.
Pèzzola
A
A
Popoli
P
P
D000818:Animals; D003342:Corpus Striatum / Q000378:metabolism*; D004195:Disease Models, Animal; D004569:Electroencephalography / Q000187:drug effects*; D005625:Frontal Lobe / Q000187:drug effects*; D006816:Huntington Disease / Q000188:drug therapy*; D008297:Male; D008845:Microinjections; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D058915:Purinergic P1 Receptor Antagonists; D017378:Quinolinic Acid / Q000633:toxicity; D051381:Rats; D017208:Rats, Wistar; D013805:Theobromine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D018696:Neuroprotective Agents; D058915:Purinergic P1 Receptor Antagonists; C057837:3,7-dimethyl-1-propargylxanthine; D017378:Quinolinic Acid; D013805:Theobromine